Study of the Frequency and of the Regulatory Function of Positive T Lymphocytes Dual CD4CD8aa (DP8a) Specific to a Bacteria of the Intestinal Microbiota (Faecalibacterium Prausnitzii) in Atopic Dermatitis, Asthma and Allergic Rhinitis

NCT ID: NCT02908360

Last Updated: 2021-09-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

56 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-07-10

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The prevalence of allergic diseases (atopic dermatitis, asthma, rhinitis, conjunctivitis and food allergy) has increased dramatically in industrialized countries over the last 20-30 years.

Allergic diseases are present especially in children and young adults, but all age groups are affected, with variations across countries and age. To propose new therapies, the investigators must first understand the physiopathology.

Since their discovery the regulatory T cells have continued to be the subject of work to understand their role in maintaining immune homeostasis in the human body but also their involvement in autoimmune diseases, inflammatory diseases, transplants of solid organs or fluids and allergic diseases.

It was identified two broad classes of regulatory T cells:

* T cells = natural regulators acquisition of a phenotype and a regulatory function right out of the thymus ( CD25 + / CD127 + low / FoxP3 +).
* T cells induced regulators = acquisition of a phenotype and a regulatory function on the periphery depending on the cytokine micro-environment.

Phenotypic characterization of these is less obvious and even more so than during the last ten years several induced regulatory T cell populations have been described ( eg, Tr1 ).

A new subpopulation of T cells induced in patients with inflammatory bowel disease recently identified have a particular phenotype as bearing the CD4 and CD8 double marking with a regulatory phenotype.

These regulatory T cells are also induced a specific of a commensal intestinal bacterium (Faecalibacterium prausnitzii).

Regarding allergies, it has been widely demonstrated a relationship between changes of the intestinal microbiota and the occurrence of allergic diseases.

The investigators would therefore propose a cross-sectional study, single-center, controlled, single blinded to study the role of T cells called double positive induced regulators DP8 to compare the frequency and the regulatory function of specific DP8 of Faecalibacterium prausnitzii in atopic dermatitis, asthma and allergic rhinitis compared to control samples.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary endpoint will be the highlight of a quantitative reduction of double positive T cells (CD4 + / CD8 +) the specific F prausnitzii peripheral blood in patients with allergic asthma, allergic rhinitis and atopic dermatitis compared to samples from a control sample collection made available by the laboratory BIOFORTISĀ® located near Nantes University of Nantes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allergic Asthma Allergic Rhinitis Atopic Dermatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with allergic rhinitis

Patients with rhinitis and / or allergic conjunctivitis duly diagnosed according to the ARIA criteria

double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse

Intervention Type GENETIC

Patients with atopic dermatitis

The patient has moderate classified atopic dermatitis (SCORAD 25 to 50) or severe (SCORAD\> 50).

double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse

Intervention Type GENETIC

Patients with allergic asthma

The patient has allergic asthma diagnosed according to the criteria GINA21

double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse

Intervention Type GENETIC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* non smoker
* BMI \<30kg/m²
* No contraindication to prick-test
* Inform consent signed for genetics
* belong to a social security scheme
* patients with allergic rhinitis or atopic dermatitis or with allergic asthma

Exclusion Criteria

* major or major incapable protected
* antimicrobial treatment (antibiotic, antifungal or antiviral)
* in contact with an MDR bacteria
* has received or is receiving specific immunotherapy
* History of cancer of the hematopoietic system
* antecedent acquired immune deficiency with HIV
* congenital immunodeficiency
* inflammatory bowel disease
* autoimmune disease and / or inflammatory
* solid organ transplant or hematopoietic cells
* addict
* pregnant or of childbearing age without effective contraception
* failure of acute or chronic severe organ
* hardly speak French and / or difficult to understand French
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nantes University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nantes University Hospital

Nantes, Pays de la Loire Region, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RC14_0372

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Oral Peanut Immunotherapy
NCT01324401 COMPLETED NA
Dupilumab Therapy for EGIDs
NCT07257835 RECRUITING
Gene Therapy for Chronic Granulomatous Disease
NCT00394316 TERMINATED EARLY_PHASE1